Dupilumab Maintains Long-Term Disease Control in Adults with Moderate-to-Severe Atopic Dermatitis as Measured by Well-Controlled Weeks: Results From the LIBERTY AD CHRONOS Clinical Trial-Reference-Cited by-同舟云学术

Dupilumab Maintains Long-Term Disease Control in Adults with Moderate-to-Severe Atopic Dermatitis as Measured by Well-Controlled Weeks: Results From the LIBERTY AD CHRONOS Clinical Trial

Published:2021-01-28 Issue:2 Volume:11 Page:327-330
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

Wu Jashin J.,Spelman Lynda,Tan Jerry L.,Etoh Takafumi,Zhang Haixin,Shumel Brad,Rossi Ana B.

Funder

Sanofi

Regeneron Pharmaceuticals

Publisher

Springer Science and Business Media LLC

Subject

Dermatology

Link

https://link.springer.com/content/pdf/10.1007/s13555-021-00487-y.pdf

Reference5 articles.

1. Sastre J, Dávila I. Dupilumab: a new paradigm for the treatment of allergic diseases. J Investig Allergol Clin Immunol. 2018;28(3):139–50.

2. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–303.

3. Langan SM, Stuart B, Bradshaw L, et al. Measuring long-term disease control in patients with atopic dermatitis: a validation study of well-controlled weeks. J Allergy Clin Immunol. 2017;140(6):1580–6.

4. Barbarot S, Rogers NK, Abuabara K, et al. Strategies used for measuring long-term control in atopic dermatitis trials: a systematic review. J Am Acad Dermatol. 2016;75(5):1038–44.

5. Howells L, Thomas KS, Sears AV, et al. Defining and measuring “eczema control”: an international qualitative study to explore the views of those living with and treating atopic eczema. J Eur Acad Dermatol Venereol. 2019;33(6):1124–32.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revisiting immunotherapeutic strategies for the management of atopic dermatitis;Exploration of Asthma & Allergy;2024-08-09

2. Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis;JAMA Dermatology;2024-08-07

3. Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry;British Journal of Dermatology;2023-05-13

4. Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis;Allergy;2022-07-29

5. Dermatitis atópica recalcitrante tratada con dupilumab: primera experiencia de manejo en el Centro Dermatológico ''Dr. Ladislao de la Pascua'', CDMX;Revista del Centro Dermatológico Pascua;2022